Market Place
Sourcing Support
BioArctic Releases 2025 Annual And Sustainability Reports
22 Apr 2026 //
PR NEWSWIRE
Nomination Committee Proposes Bioarctic AB Board Members
27 Mar 2026 //
PR NEWSWIRE
Bioarctic AB (Publ) Reports Share And Voting Figures
27 Feb 2026 //
PR NEWSWIRE
BioArctic Interim Report for the period October - December 2025
18 Feb 2026 //
PR NEWSWIRE
BioArctic To Present Q4 2025 Report On Feb 18 At 9.30 A.M. CET
11 Feb 2026 //
PR NEWSWIRE
Leqembi® Sales Reach $20.7B In Q4 2025
06 Feb 2026 //
PR NEWSWIRE BIO
Interim Report For The Period July - September 2025: Bioarctic
13 Nov 2025 //
PR NEWSWIRE
Bioarctic To Present Q3 Report On November 13
04 Nov 2025 //
PR NEWSWIRE
Sales of Leqembi Totaled 18 Billion Yen in Third Quarter 2025
30 Oct 2025 //
PR NEWSWIRE
BioArctic`s Gunilla Osswald Wins Uppsala University Alumnus 2025
09 Sep 2025 //
PR NEWSWIRE
BioArctic`s Founders Plan to Divest Minor Part of Shareholding
03 Sep 2025 //
PR NEWSWIRE
BioArctic`s Q2 Report for April-June 2025 Presentation on Aug 28
21 Aug 2025 //
PR NEWSWIRE
BioArctic`s Capital Markets Day 2025: New Growth Era
02 Jun 2025 //
PR NEWSWIRE
Exidavnemab Phase 1 Study Results Published In Clinical Pharmacology
27 Aug 2024 //
PR NEWSWIRE
BioArctic Comments On Lecanemab Approval Rumors In Britain
22 Aug 2024 //
PR NEWSWIRE
BioArctic To Present Q2 2024 Report On August 29
19 Aug 2024 //
PR NEWSWIRE
Leqembi Revenue Doubles In Q2 2024
01 Aug 2024 //
PR NEWSWIRE
Long-Term Lecanemab Data Shows Increased Benefit With Maintained Safety
30 Jul 2024 //
PR NEWSWIRE
Leqembi approved for the treatment of Alzheimer`s disease in Hong Kong
10 Jul 2024 //
PRESS RELEASE
Eisai and Biogen launch Alzheimer`s drug Leqembi in China
28 Jun 2024 //
REUTERS
Eisai Projects Leqembi Revenue JPY 56.5B For FY2024
15 May 2024 //
PR NEWSWIRE
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
24 Apr 2024 //
PR NEWSWIRE
The Nomination Committee Proposes Board, Chair Election for BioArctic AB
16 Apr 2024 //
PR NEWSWIRE
BioArctic`s ESG Focus Qualifies for Nasdaq Stockholm Index
10 Apr 2024 //
PR NEWSWIRE
EU regulator delays decision on Eisai-Biogen Alzheimer`s drug
23 Mar 2024 //
REUTERS
BioArctic: Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer`s
19 Mar 2024 //
PR NEWSWIRE
BioArctic`s partner Eisai presents sales simulation for Leqembi
07 Mar 2024 //
PR NEWSWIRE
Sales of Leqembi® totaled 1.1 billion yen in the fourth quarter 2023
05 Feb 2024 //
PR NEWSWIRE
Leqembi® approved for the treatment of Alzheimer`s disease in China
09 Jan 2024 //
PR NEWSWIRE
Update relating to LEQEMBI from presentation of quarterly report published
07 Nov 2023 //
PR NEWSWIRE
LEQEMBI® Q3 2023 sales published - 0.4 billion yen recorded in the period
07 Nov 2023 //
PR NEWSWIRE
BioArctic moves to Nasdaq Stockholm Large Cap
02 Jan 2023 //
PR NEWSWIRE
BioArctic`s partner Eisai initiates BLA submission of data for lecanemab
21 Dec 2022 //
PRNEWSWIRE
BioArctic expands portfolio with alpha-synuclein Brain Transporter project
17 Nov 2022 //
PRNEWSWIRE
BioArctic receives patent in US for blood-brain barrier transport technology
14 Nov 2022 //
PRNEWSWIRE
BioArctic develops new treatment for Gaucher’s disease
09 Nov 2022 //
PHARMABIZ
Lecanemab PIII study in Alzheimer`s disease meets primary & secondary endpoints
27 Sep 2022 //
PRNEWSWIRE
BioArctic receives new drug substance patent in the US for ABBV-0805
05 May 2022 //
PRNEWSWIRE
AbbVie breaks off Parkinson`s deal with biotech partner
21 Apr 2022 //
ENDPTS
Invitation to presentation of BioArctic`s Q1 Report
20 Apr 2022 //
PRNEWSWIRE
Latest lecanemab data to be presented at the AD/PD congress
11 Mar 2022 //
PRNEWSWIRE
BioArctic continues to build its commercial organization
18 Feb 2022 //
PRNEWSWIRE
New data on lecanemab presented at the CTAD Alzheimer conference
15 Nov 2021 //
PRNEWSWIRE
BioArctic develops new antibody treatment for ALS
15 Nov 2021 //
PRNEWSWIRE
New data published on ABBV-0805 in Neurobiology of Disease
08 Nov 2021 //
PRNEWSWIRE
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer`s disease
23 Jun 2021 //
PRNEWSWIRE
BioArctic receives patent in Japan for new antibodies targeting A`s disease
11 May 2021 //
PRNEWSWIRE
Lecanemab (BAN2401) Phase 2b study in early Alzheimer`s disease published in pee
20 Apr 2021 //
PRNEWSWIRE
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021
15 Mar 2021 //
PRNEWSWIRE
Eisai increases the number of participants in Clarity AD study
03 Feb 2021 //
PRNEWSWIRE
BioArctic`s partner Eisai to present latest data on BAN2401 at CTAD conference
28 Oct 2020 //
PRNEWSWIRE
BioArctic`s to Present Interim Report for the period Jan-Sept 2020 on October 14
06 Oct 2020 //
PRNEWSWIRE
BioArctic`s Partner Eisai to Present Update on the Development of BAN2401
21 Jul 2020 //
PRNEWSWIRE
BioArctic and University of Oslo Sign Research Agreement Apolipoprotein E
29 Jun 2020 //
PRNEWSWIRE
Members of BioArctic`s Board of Directors and Management Increase
26 May 2020 //
PR NEWSWIRE
Alzheimer Patients at Swedish Clinics to be Included in Ph3 Study BAN2401
03 Mar 2020 //
PR NEWSWIRE
BioArctic announces research collaboration with Eisai regarding BAN2401
18 Dec 2019 //
CONTRACT PHARMA
Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study
05 Dec 2019 //
PR NEWSWIRE
BioArctic Announces Results From Interim Analysis of Phase 1/2 Study of SC0806
18 Nov 2019 //
BIOSPACE
BioArctic and Eisai to Present BAN2401
10 Jul 2019 //
PR NEWSWIRE
